Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Lang
A E
AE
Kleiner-Fisman
G
G
Saint-Cyr
J A
JA
Miyasaki
J
J
Lozano
A
A
D003221:Confusion / Q000139:chemically induced; D003863:Depression / Q000139:chemically induced; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004401:Dysarthria / Q000139:chemically induced; D004599:Electric Stimulation Therapy; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000628:therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D020531:Subthalamic Nucleus / Q000502:physiology; D013995:Time; D016896:Treatment Outcome
D018491:Dopamine Agonists; D007980:Levodopa